精神分裂症背外侧前额叶皮质的神经元特异性生物能量过程缺陷
该研究检测精神分裂症患者背外侧前额叶皮质(DLPFC)的生物能量通路,发现己糖激酶和磷酸果糖激酶活性及PFK1 mRNA表达下降,锥体神经元中HXK1、PFK1、GLUT1和GLUT3 mRNA表达减少而MCT1 mRNA表达增加,提示DLPFC存在异常生物能量功能及神经元特异性葡萄糖利用缺陷。
要点
- 精神分裂症DLPFC中己糖激酶和磷酸果糖激酶活性降低,PFK1 mRNA表达下降。
- 锥体神经元中HXK1、PFK1、GLUT1和GLUT3 mRNA表达减少,MCT1 mRNA表达增加。
- 结果提示精神分裂症DLPFC存在神经元特异性葡萄糖利用缺陷。
核心结论
- 精神分裂症DLPFC存在异常生物能量功能及神经元特异性葡萄糖利用缺陷。
研究设计与样本
- 研究采用Western blot、定量实时PCR及酶/底物测定分析精神分裂症患者与对照者DLPFC生物能量通路。
- 采用激光捕获显微切割-定量PCR在细胞水平检测这些通路。
主要发现
- DLPFC中己糖激酶(HXK)和磷酸果糖激酶(PFK)活性降低,PFK1 mRNA表达下降。
- 锥体神经元中单羧酸转运体1(MCT1)mRNA表达增加。
- 锥体神经元中HXK1、PFK1、葡萄糖转运体1(GLUT1)和GLUT3 mRNA表达减少。
关键数值与推荐
- DLPFC中HXK和PFK活性降低及PFK1 mRNA表达下降为关键酶学与表达改变。
- 锥体神经元中MCT1 mRNA表达增加,HXK1、PFK1、GLUT1和GLUT3 mRNA表达减少为细胞水平改变。
临床怎么用
- 关注精神分裂症DLPFC生物能量通路及神经元葡萄糖利用缺陷作为潜在病理生理机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Schizophrenia is a devastating illness that affects over 2 million people in the United States and costs society billions of dollars annually. New insights into the pathophysiology of schizophrenia are needed to provide the conceptual framework to facilitate development of new treatment strategies. We examined bioenergetic pathways in the dorsolateral prefrontal cortex (DLPFC) of subjects with schizophrenia and control subjects using western blot analysis, quantitative real-time polymerase chain reaction, and enzyme/substrate assays. Laser-capture microdissection-quantitative polymerase chain reaction was used to examine these pathways at the cellular level. We found decreases in hexokinase (HXK) and phosphofructokinase (PFK) activity in the DLPFC, as well as decreased PFK1 mRNA expression. In pyramidal neurons, we found an increase in monocarboxylate transporter 1 mRNA expression, and decreases in HXK1, PFK1, glucose transporter 1 (GLUT1), and GLUT3 mRNA expression. These results suggest abnormal bioenergetic function, as well as a neuron-specific defect in glucose utilization, in the DLPFC in schizophrenia.
引用
- Sullivan CR, Koene RH, Hasselfeld K, et al. Neuron-specific deficits of bioenergetic processes in the dorsolateral prefrontal cortex in schizophrenia. Mol Psychiatry. 2018. PMID: 29497148. doi:10.1038/s41380-018-0035-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。